<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669786</url>
  </required_header>
  <id_info>
    <org_study_id>VLC-EB-0103-0408-1</org_study_id>
    <nct_id>NCT00669786</nct_id>
  </id_info>
  <brief_title>Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles</brief_title>
  <official_title>Highly Purified Human Menopausal Gonadotropin Versus Recombinant Follicle Stimulating Hormone in Ovarian Hyperstimulation With Gonadotropin Releasing Hormone Antagonists. A Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial comparing the ongoing pregnancy rate (primary end-point) in 280
      patients undergoing IVF/ICSI after stimulation with hp-hMG or rFSH controlled with a GnRH
      antagonist. Non significant differences were observed between hp-hMG and rFSH in terms of the
      ongoing pregnancy rate per started cycle (35.0% vs. 32.1%; p=0.61); R.R: 1.09 (95% CI:
      0.78-1.51; Risk Difference: 2.9%). No differences were observed for implantation, clinical
      pregnancy and pregnancy loss rates. Patients receiving rFSH obtained more oocytes (14.4 ± 8.1
      vs. 11.3 ± 6.0; p=0.001). Estradiol was higher at the end of stimulation in the hp-hMG group,
      while Progesterone was higher in patients stimulated with rFSH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>HMG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Human Menopausal Gonadotropin (HMG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>r-FSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant Follicle Stimulating Hormone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Menopausal Gonadotropin (HMG) &amp; - Recombinant Follicle Stimulating Hormone (r-FSH)</intervention_name>
    <arm_group_label>HMG</arm_group_label>
    <arm_group_label>r-FSH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with good physical and mental health

          -  aged 18-37 years

          -  regular menstrual cycles ranging from 25 to 35 days; body mass index (BMI) &lt; 30 kg/m2

          -  normal basal serum FSH (≤ 10 IU/L) and E2 (≤ 75 pg/mL) levels determined on the day 3
             of the cycle previous to COH

          -  no uterine (fibroids, adenomyosis, mullerian malformations), ovarian (endometrioma,
             polycystic ovaries) or adnexa (hydrosalpinx) abnormalities assessed by vaginal
             ultrasound.

        Exclusion Criteria:

          -  patients with a history of recurrent pregnancy loss

          -  any significant systemic disease, endocrine or metabolic disorder

          -  having concomitant medication interfering with the purposes of the study

          -  patients who have received any ovulation induction drug within one month before their
             inclusion in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Valenciano de Infertilidad</name>
      <address>
        <city>Valencia</city>
        <zip>46117</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2008</study_first_posted>
  <last_update_submitted>April 30, 2008</last_update_submitted>
  <last_update_submitted_qc>April 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2008</last_update_posted>
  <keyword>Ongoing Pregnancy Rate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

